LXRX

Lexicon Pharmaceuticals, Inc.

Healthcare
Biotechnology
$888M market cap

Forecast run · Sep 14, 2026Upside rank 588 of 3,136

Model Signal

ForecastQ Daily Probabilities

53.6%

33.5%

29.2%

Analyst Consensus

Recommendation2.79/5 Hold

Last price$2.00

Price target$6.00

Implied move+200.0%

Analysts14

ForecastQ Portfolios

LXRX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.